Avlayah Injection, Powder, Lyophilized, For Solution
Product Images NDC 84976-001

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Avlayah (NDC 84976-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denali Therapeutics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (150 mg Vial Label)

Label for AVLAYAH (tividenofusp alfa-eknm) 150 mg/vial injection, powder, lyophilized, for solution, intended for intravenous use. The label includes storage instructions to refrigerate at 2 to 8°C and to protect from light. It states the product is manufactured by Denali Therapeutics Inc., South San Francisco, CA, and notes the product is for single-dose vial use with unused portion to be discarded.*

FDA Label Image

Principal Display Panel (150 mg Vial Carton)

Packaging label for AVLAYAH (tividenofusp alfa-eknm) injection, lyophilized powder for solution, 150 mg per vial. The label indicates it is for intravenous infusion after reconstitution and dilution. The labeler is Denali Therapeutics Inc., located in South San Francisco, CA. Storage instructions and inactive ingredients are also shown, with the product NDC number 84976-001-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.